Menu
Recruiting NCT05994209

Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors

Phase I Interventional Nicotine Vaping Nicotine Use Disorder

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: quitSTART Mobile Application, Chatbot Feature in quitSTART Mobile Application.
Who it may be relevant to
Registry conditions: Nicotine Vaping, Nicotine Use Disorder. Basic parameters: 15 years — 25 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Use of vaping products (e.g., electronic nicotine delivery systems, e-cigarettes) has been increasing rapidly, particularly among teens and young adults. With limited information on the long-term effects of vaping products, health information about vaping has been somewhat unclear in regards to associated health risks. Teens and young adults may be reluctant to disclose their use of vaping products to parents or health providers and instead turn to social media to share and seek out information regarding vaping risks and cessation supports. Thus, our current proposal outlines the use of social media to identify teens and young adults socially networking about vaping, the use of an online chatbot screen to evaluate individual cessation support needs, and the use of a digital intervention system to support vaping cessation. The mobile intervention used in this study is based on a widely-used evidence-based mobile intervention for combustible smoking (i.e., quitSTART) and has been adapted for vaping and young adults to include an in-app chatbot to guide users to tailored content and to motivate and encourage their cessation efforts. We aim to integrate our social media recruitment and online screening approach to connect individuals with this mobile app intervention, and will conduct a randomized controlled trial to evaluate user engagement with and preliminary efficacy of the digital intervention on reducing vaping behaviors among teens and young adults.

Interventions

  • Device quitSTART Mobile Application
    Mobile application with educational content, motivational messages, self-monitoring, and tips for managing cravings to support vaping cessation among young adults.
  • Behavioral Chatbot Feature in quitSTART Mobile Application
    In-App chatbot feature emedded into quitSTART mobile application to motivate vaping cessation and support app navigation.

Primary outcome measures

  • Vaping cessation [Time frame: Baseline, 6 weeks, 3 months]
Secondary outcome measures (3)
  • Nicotine dependence [Time frame: Baseline, 6 weeks, 3 months]
  • Risk perception related to vaping [Time frame: Baseline, 6 weeks, 3 months]
  • Intervention engagement [Time frame: Baseline, 6 weeks, 3 months]

Eligibility criteria

Inclusion criteria

  • US Resident
  • English Speaking
  • Have daily access to a smartphone
  • Current vaping product user (P30D)
  • Identified as socially networking about a desire to quit vaping and/or experiencing negative health outcomes due to vaping
  • Vaping product user only (i.e., not using vaping as a means to support combustible smoking cessation)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • Washington University in St. Louis, School of Medicine — St Louis

Identifiers

NCT: NCT05994209 · 1R34DA054725-01A1 · R34DA054725

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗